Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 238-243

  Solas, Caroline ^d   Lafeuillade, Alain ^a,c   Halfon, Philippe ^b   Chadapaud, Stéphane ^a   Hittinger, Gilles ^a   Lacarelle, Bruno ^d  

^a Laboratory of Virology Alphabio   (France)

^b GENERAL HOSPITAL   (France)

^c Hopital Chalucet Toulon   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FEMALE; GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOID TISSUE; MALE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; TISSUE DISTRIBUTION; VIRAL LOAD;

EID: 12244294518     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.238-243.2003     Document Type: Article

References (33)

1. Byrn, R. A., and A. A. Kiessling. 1998. Analysis of human immunodeficiency virus in semen: indication of a genetically distinct virus reservoir. J. Reprod. Immunol. 41:161-176.
2. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y. H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo, and R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
3. Chun, T. W., L. Stuyver, and S. B. Mizell. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
4. DiStefano, M., J. R. Fiore, L. Monno, A. Lepera, G. Pastore, and G. Angarano. 1999. Detection of multiple drug-resistance-associated pol mutations in cervicovaginal secretions from women. AIDS 13:992-994.
5. Durant, J., P. Clevenbergh, R. Garraffo, P. Halfon, S. Icard, P. Del Giudice, N. Montagne, J. M. Schapiro, and P. Dellamonica. 2000. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacologic data from the Viradapt Study. AIDS 14:1333-1339.
6. Enting, R. H., M. Hoetelmans, J. M. A. Lange, D. M. Burger, J. H. Beijnen, and P. Portegies. 1998. Antiretroviral drugs and the central nervous system. AIDS 12:1941-1955.
7. Eron, J. J., P. L. Vernazza, D. M. Johnston, F. Seillier-Moiseiwitsch, T. M. Alcorn, S. A. Fiscus, and M. S. Cohen. 1998. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 12:F181-F189.
8. Gallant, J. 2000. Strategies for long-term success in the treatment of HIV infection JAMA. 283:1329-1334.
9. Groothuis, D., and R. Levy. 1997. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. 3:387-400.
10. Günthard, H., D. Havlir, S. Fiscus, Z. Zhang, J. Eron, J. Mellors, R. Gulick, S. Frost, A. Leigh Brown, W. Schleif, F. Valentine, L. Jonas, A. Meibohm, C. Ignacio, R. Isaacs, R. Gamagami, E. Emini, A. Haase, D. Richman, and J. Wong. 2001. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J. Infect. Dis. 183:1318-1327.
11. Haas, D. W., J. Stone, L. A. Clough, B. Johnson, P. Spearman, V. L. Harris, J. Nicotera, R. H. Johnson, S. Raffanti, L. Zhong, P. Bergqwist, S. Chamberlin, V. Hoagland, and W. D. Ju. 2000. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type I infection. Clin. Pharmacol. Ther. 68:367-374.
12. Hoetelmans, R. 1998. Sanctuary sites in HIV-1 infection. Antivir. Ther. 3:S13-S17.
13. Jayewardene, A. L., F. Zhu, F. T. Aweeka, and J. G. Gambertoglio. 1998. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J. Chromatogr. B 707:203-211.
14. Kiessling, A., L. Fitzgerald, D. Zhang, H. Chhay, D. Brettler, R. Eyre, J. Steinberg, K. McGowan, and R. Byrn. 1998. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res. Hum. Retrovir. 14(Suppl. 1):S33-S41.
15. Lafeuillade, A., L. Chollet, G. Hittinger, N. Profizi, O. Costes, and C. Poggi. 1997. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J. Infect. Dis. 177:235-238.
16. Lafeuillade, A., C. Poggi, A. Tamalet, and N. Profizi. 1997. Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments. J. Infect. Dis. 176:804-806.
17. Letendre, S. L., E. V. Capparelli, R. J. Ellis, J. A. McCutchan, and the HIV Neurobehavioral Research Center Group. 2000. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 44:2173-2175.
18. Mayer, K. H., S. Boswell, R. Goldstein, W. Lo, C. Xu, L. Tucker, M. P. DePasquale, R. D'Aquila, and D. Andreson. 1999. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin. Infect. Dis. 28:1252-1259.
19. Mocroft, A., H. Devereux, S. Kinloch-de-Loes, M. Wilson, D., S. M. Youle, M. Tyrer, C. Loveday, A. Phillips, M. Johnson, et al. 2000. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS 14:1545-1552.
20. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human deficiency virus. Virology 250:255-262.
21. Moyle, G. J., M. Sadler, and N. Buss. 1999. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Clin. Infect. Dis. 28:403-404.
22. Palella, F. J. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
23. Pereira, A., A. Kashuba, S. Fiscus, J. Hall, R. Tidwell, L. Troiani, J. Dunn, J. J. Eron, and M. Cohen. 1999. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J. Infect. Dis. 180:2039-2043.
24. Pomerantz, R. J. 1999. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N. Engl. J. Med. 340:1672-1674.
25. Schockmel, G., S. Yerly, and L. Perrin. 1997. Detection of low HIV-1 RNA levels in plasma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:179-183.
26. Schrager, L. K., and M. P. D'Souza. 1998. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67-71.
27. Si-Mohamed, A., M. Kazatchkine, I. Heard, C. Goujon, T. Prazuck, G. Aymard, G. Cessot, Y. Kuo, M. Bernard, B. Diquet, J. Malkin, L. Gutmann, and L. Belec. 2000. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J. Infect. Dis. 182:112-122.
28. Tachet, A., E. Dulioust, D. Salmon, M. De Almeida, S. Rivalland, L. Finkielsztejn, I. Heard, P. Jouannet, D. Sicard, and C. Rouzioux. 1999. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 13:823-831.
29. Tang, Y. W., J. T. Huong, R. M. Lloyd, P. Spearman, and D. W. Haas. 2000. Comparison of human immunodeficiency virus type I RNA sequence heterogeneity in cerebrospinal fluid and plasma. J. Clin. Microbiol. 38:4637-4639.
30. Taylor, S., D. Back, S. Drake, J. Workman, H. Reynolds, S. Gibbons, D. White, and D. Pillay. 2001. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J. Antimicrob. Chemother. 48:351-354.
31. Taylor, S., D. J. Back, J. Workman, S. M. Drake, D. J. White, B. Choudhury, P. A. Cane, G. M. Beards, K. Halifax, and D. Pillay. 1999. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 13:859-872.
32. Wu, E. Y., J. M. Wilkinson, D. G. Naret, V. L. Daniels, L. J. Williams, D. A. Khalil, and B. V. Shetty. 1997. High performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J. Chromatogr. B 695:373-380.
33. Zhou, X. J., D. V. Havlir, D. D. Richman, E. P. Acosta, M. Hirsch, A. C. Collier, P. Tebas, J. P. Sommadossi, and the AIDS Clinical Trials Group Study 343. 2000. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 14:2869-2876.